Strategic Initiative

Slingshot members are tracking this corporate initiative:

Lannett Company plans to co-develop generic insulin for the U.S. market with its strategic partner in China, YiChang HEC ChangJiang Pharmaceutical, an HEC Group company. The product is currently in late stage development

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
LCI Community voting in process
1558.HK Community voting in process

Additional Information

Additional Relevant Details  Lannett will manage the remaining clinical and regulatory steps specific for a U.S. Food and Drug Administration (FDA) license to market. Lannett has the exclusive U.S. marketing rights to the product.  
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Apr 22, 2016
Projected Implementation:
Q2, 2016
Relevance Tracked Until:
Q1, 2017
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Generic Insulin, Oseltamivir Phosphate, Anti-viral Products, Generic Pharmaceutical Products